A Prospective, Open, Observational Study to Confirm the Lipid-lowering Effect, Changes in Glucose Metabolism, and Safety After 6 Months of Administration of Atostazet to Hypercholesterolemic Patients 65 Years of Age or Older

Inclusion Criteria: * Males or females aged ≥ 65 years * Primary Hypercholesterolemia * moderate risk or higher patient based on Korean Guidelines for the Management of Dyslipidemia (the 4th edition) Exclusion Criteria: * Patients with a known hypersensitivity to any of the major or minor components of the study drug * Patients with active hepatic disease or unexplained persistently elevated serum aminotransferase levels * Patients with myopathies * Patients receiving glecaprevir and pibrentasvir